Zurich Cantonal Bank
AXSM icon

Zurich Cantonal Bank’s Axsome Therapeutics AXSM Stock Holding History

Zurich Cantonal Bank’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Buy
10,636
+1,232
+13% +$267K 0.01% 984
2026
Q1 		$1.59M Buy
9,404
+1,940
+26% +$335K ﹤0.01% 1161
2025
Q4 		$1.36M Buy
7,464
+475
+7% +$66.3K ﹤0.01% 1162
2025
Q3 		$849K Buy
6,989
+541
+8% +$60.9K ﹤0.01% 1383
2025
Q2 		$673K Buy
6,448
+911
+16% +$96.5K ﹤0.01% 1471
2025
Q1 		$646K Sell
5,537
-1,479
-21% -$168K ﹤0.01% 1433
2024
Q4 		$594K Buy
7,016
+1,817
+35% +$167K ﹤0.01% 1526
2024
Q3 		$467K Hold
5,199
– – ﹤0.01% 1607
2024
Q2 		$419K Hold
5,199
– – ﹤0.01% 1609
2024
Q1 		$415K Sell
5,199
-635
-11% -$53.3K ﹤0.01% 1600
2023
Q4 		$464K Sell
5,834
-1,890
-24% -$126K ﹤0.01% 1552
2023
Q3 		$540K Buy
7,724
+872
+13% +$65.2K ﹤0.01% 1351
2023
Q2 		$492K Buy
6,852
+1,129
+20% +$83.3K ﹤0.01% 1361
2023
Q1 		$353K Buy
5,723
+1,031
+22% +$67.7K ﹤0.01% 1511
2022
Q4 		$362K Sell
4,692
-239
-5% -$14.3K ﹤0.01% 1440
2022
Q3 		$220K Buy
4,931
+1,167
+31% +$58.3K ﹤0.01% 1693
2022
Q2 		$144K Sell
3,764
-63
-2% -$1.99K ﹤0.01% 1985
2022
Q1 		$158K Buy
3,827
+831
+28% +$25.8K ﹤0.01% 2040
2021
Q4 		$113K Hold
2,996
– – ﹤0.01% 2438
2021
Q3 		$99K Hold
2,996
– – ﹤0.01% 2340
2021
Q2 		$202K Hold
2,996
– – ﹤0.01% 1800
2021
Q1 		$170K Sell
2,996
-539
-15% -$37.9K ﹤0.01% 1870
2020
Q4 		$288K Buy
3,535
+507
+17% +$37.9K ﹤0.01% 1611
2020
Q3 		$216K Hold
3,028
– – ﹤0.01% 1538
2020
Q2 		$249K Buy
3,028
+471
+18% +$36.3K ﹤0.01% 1385
2020
Q1 		$150K Buy
2,557
+373
+17% +$30.4K ﹤0.01% 1363
2019
Q4 		$226K Hold
2,184
– – ﹤0.01% 1270
2019
Q3 		$44K Sell
2,184
-607
-22% -$15.6K ﹤0.01% 2123
2019
Q2 		$72K Buy
+2,791
New +$55.9K ﹤0.01% 1827

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zurich Cantonal Bank's AXSM Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Axsome Therapeutics (AXSM) stake by 13% in Q2 2026, buying an estimated $267K and bringing the position to 10,636 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #984.

Zurich Cantonal Bank first reported a position in AXSM in Q2 2019 and has held it in 29 quarters since. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Zurich Cantonal Bank held 10,636 shares of Axsome Therapeutics worth $2.6M as of Q2 2026.
  • Zurich Cantonal Bank bought 1,232 Axsome Therapeutics shares in Q2 2026, an estimated $267K.
  • Axsome Therapeutics made up 0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #984 holding.
  • Zurich Cantonal Bank first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.